NextCure (NXTC) grants 8,270 stock options to Sr VP, General Counsel

Rhea-AI Filing Summary

NextCure, Inc. reported that its Sr VP and General Counsel, Kevin G. Shaw, received an employee stock option grant. On January 30, 2026, he was awarded an option to buy 8,270 shares of common stock at an exercise price of $10.85 per share.

According to the vesting schedule, one fourth of the option vests on January 30, 2027, and the remaining three fourths vest in 36 monthly installments beginning February 28, 2027. Following this grant, he beneficially holds 8,270 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shaw Kevin G.

Role Sr VP, General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	8,270	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 8,270 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shaw Kevin G.

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr VP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.85	01/30/2026		A		8,270		(1)	01/29/2036	Common Stock	8,270	$0	8,270	D

Explanation of Responses:

1. One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

	/s/ Steven P. Cobourn, as attorney-in-fact for Kevin G. Shaw	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NextCure (NXTC) report for Kevin G. Shaw?

NextCure reported that Sr VP and General Counsel Kevin G. Shaw received an employee stock option grant. On January 30, 2026, he was awarded options to buy 8,270 shares of common stock at an exercise price of $10.85 per share.

How many NextCure (NXTC) shares are covered by Kevin G. Shaws new options?

The new employee stock option grant covers 8,270 shares of NextCure common stock. These options give him the right to purchase that number of shares at a fixed $10.85 exercise price, subject to the disclosed vesting schedule over time.

What is the exercise price of Kevin G. Shaws NextCure (NXTC) stock options?

The employee stock option grant to Kevin G. Shaw has an exercise price of $10.85 per share. This means he can buy NextCure common stock at $10.85 once the options vest and become exercisable, regardless of future market prices.

When do Kevin G. Shaws NextCure (NXTC) options start vesting?

One fourth of Kevin G. Shaws stock options vest on January 30, 2027. The remaining three fourths then vest in 36 equal monthly installments beginning on February 28, 2027, creating a long-term, time-based vesting schedule for the award.

How many NextCure (NXTC) stock options does Kevin G. Shaw hold after this grant?

After this reported transaction, Kevin G. Shaw beneficially owns 8,270 employee stock options directly. All of these options relate to NextCure common stock and are subject to time-based vesting starting in 2027, as detailed in the filing footnote.

Is the reported NextCure (NXTC) Form 4 transaction a purchase or an option grant?

The reported Form 4 transaction is an employee stock option grant, coded as an acquisition (A) of derivative securities. It does not represent an open-market stock purchase but the award of options to buy 8,270 shares at $10.85 per share.